[{"id":"55adb811-b891-4933-bcb8-86892c74e47f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04752163","created_at":"2021-02-12T13:55:51.280Z","updated_at":"2024-07-02T16:35:29.212Z","phase":"Phase 1/2","brief_title":"DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04752163","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3 • NPM1","pipe":" | ","alterations":" NPM1 mutation","tags":["FLT3 • NPM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • azacitidine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • emilumenib succinate (DS-1594) • mesna • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • Noxafil (posaconazole) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 03/25/2021","start_date":" 03/25/2021","primary_txt":" Primary completion: 11/08/2023","primary_completion_date":" 11/08/2023","study_txt":" Completion: 11/08/2023","study_completion_date":" 11/08/2023","last_update_posted":"2023-11-15"}]